Influence of pneumococcal serotype group on outcome in adults with bacteraemic pneumonia

Eur Respir J. 2010 Nov;36(5):1073-9. doi: 10.1183/09031936.00176309. Epub 2010 Feb 11.

Abstract

The influence of infecting serotype group on outcome in bacteraemic pneumococcal pneumonia remains unclear. We performed a prospective, 10-yr observational study in an 800-bed teaching hospital. 299 adults diagnosed with pneumonia whose blood cultures showed growth of Streptococcus pneumoniae were included in the study. High invasive disease potential (H) serotypes included serotypes 1, 5 and 7F, which served as a reference category, were compared with low invasive disease potential (L) serotypes (3, 6A, 6B, 8, 19F, and 23F) and other (O) serotypes (non-H, non-L). The influence on outcome was determined for each group of serotypes after adjusting for underlying conditions and severity of illness at admission. Overall, 30-day mortality was 11%. H serotypes (n = 93) infected primarily younger people and presented a higher risk of complicated parapneumonic effusion or empyema (17.2 versus 5.1%; p = 0.01), with lower mortality (3.2%). The isolation of L serotypes (n = 78) was an independent risk factor for 30-day mortality (OR 7.02, 95% CI 1.72-28.61), as were Charlson score (OR 1.30, 95% CI 1.08-1.58), alcohol abuse (OR 3.99, 95% CI 1.39-11.39) and severity of illness measured by American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) criteria (OR 4.80, 95% CI 1.89-12.13). A vaccination strategy including serotypes 3, 6A, 6B, 8, 19F and 23F may improve survival in adults.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Comorbidity
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pneumococcal Vaccines / therapeutic use
  • Pneumonia, Pneumococcal / microbiology*
  • Pneumonia, Pneumococcal / mortality*
  • Pneumonia, Pneumococcal / prevention & control
  • Prevalence
  • Prospective Studies
  • Risk Factors
  • Serotyping
  • Severity of Illness Index*
  • Streptococcus pneumoniae / classification*
  • Vaccines, Conjugate / therapeutic use

Substances

  • Pneumococcal Vaccines
  • Vaccines, Conjugate